According to the report published by Allied Market Research, the global Hormone Replacement Therapy Market generated $31.06 billion in 2019, and is estimated to garner $46.50 billion by 2027, witnessing a CAGR of 5.1% from 2020 to 2027. The report provides a detailed analysis of changing market trends, key winning strategies, top investment pockets, major segments, value chain, and competitive scenario.
Increase in prevalence of menopausal disorder, rise in awareness regarding post-menopausal issues among women, and advent of novel hormone replacement therapies drive the growth of the global hormone replacement therapy market. However, adverse effects of the therapy and high cost of treatment restrain the market growth. On the other hand, emergence of telemedicine would offer new opportunities in the next few years.
Covid-19 scenario-
Fertility treatments and post menopause have been stopped during the pandemic as there have been evidences that outlined that lesser estrogen levels posed more risks regarding the disease infection in older women. In addition, the hormone withdrawal may accelerate the progression of the virus in the bodies.
Owing to lockdown and shift in focus toward prevention and treatment of corona-infected patients, many therapies have been postponed. However, the therapies would restart during the post-lockdown.
By therapy type, the estrogen hormone replacement therapy segment accounted for more than two-fifths of the total market share in 2019, and is estimated to maintain its leadership status by 2027. However, the human growth hormone replacement therapy segment is expected to manifest the highest CAGR of 7.1% from 2020 to 2027.
By region, North America contributed to the highest market share in terms of revenue in 2019, accounting for more than two-fifths of the global hormone replacement therapy market, and will maintain its lead status during the forecast period. On the other hand, Asia-Pacific would portray the fastest CAGR of 7.1% from 2020 to 2027.
Leading players of the global hormone replacement therapy market analyzed in the research include Bayer AG, Abbott Laboratories, F. Hoffmann-La Roche Ltd. (Genentech, Inc.), Eli Lilly and Company, Merck KGaA, Hisamitsu Pharmaceutical Co., Inc. (Noven Pharmaceuticals, Inc.), Novartis International AG, Mylan N.V. (Viatris Inc.), Novo Nordisk A/S, and Pfizer Inc.